---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022971"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:16:40.963817+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harrow Q2 revenue $63.7M (+30% YoY); net income $5M; VEVYE on track for >$100M; adds Samsung Bioepis

## Summary
- Total revenues $63.7M, up 30% YoY; GAAP net income $5.0M vs loss of $6.5M; Adj EBITDA $17.0M (up from $8.8M).
- VEVYE dry eye revenue on track to exceed $100M in 2025; Q2 market share 7.8%; 66% sequential prescription growth.
- IHEEZO revenue $18.3M (+62% YoY, +251% QoQ); TRIESENCE added 870 new accounts YTD; unit growth 32% QoQ.
- Secured exclusive U.S. rights to Samsung Bioepis ophthalmic biosimilars (BYOOVIZ, OPUVIZ) in July 2025.
- Acquired U.S. rights for BYQLOVI (clobetasol) in June 2025; Apollo Care alliance to expand VEVYE access.

## SEC filing metadata
- accession: 0001641172-25-022971
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000164117225022971/0001641172-25-022971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000164117225022971/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022971
- JSON: https://secwatch.observer/filing/0001641172-25-022971.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022971.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.